Masite Sehadet Senol

Mrs. Masite Sehadet Senol


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
STSeval Tasdemir
Seval Tasdemir
MBMuhammet Volkan Bülbül
Muhammet Volkan Bülbül
BKBetul Kalay
Betul Kalay
MSMasite Sehadet Senol
Masite Sehadet Senol
STSafak Tavukcuoglu
Safak Tavukcuoglu
ESEge Can Serefoglu
Ege Can Serefoglu
Background: Melatonin concentrations in follicular fluid exceed serum levels, suggesting local ovarian accumulation and a potential role in the follicular microenvironment. Previous studies reporting associations between intrafollicular melatonin and IVF outcomes have largely relied on dominant-follicle sampling. This study evaluated pooled follicular-fluid melatonin concentrations across clinical ovarian-response phenotypes in women undergoing standardized melatonin-supplemented IVF-ICSI cycles. Methods: Seventy-one women undergoing controlled ovarian stimulation with a GnRH antagonist protocol were prospectively enrolled. All participants received oral melatonin at 3 mg/day) from gonadotropin initiation until oocyte retrieval. Participants were classified as poor (n = 24), normal (n = 22), or high responders (n = 25) using predefined clinical ovarian-response criteria. Pooled follicular fluid was collected during oocyte retrieval and melatonin was measured by ELISA. Age-adjusted and multivariable models were used to re-evaluate between-group melatonin differences, the AMH–melatonin association, and the relationship between melatonin and retrieved oocyte number. Results: In the unadjusted analysis, pooled follicular-fluid melatonin concentrations differed across ovarian -response groups (p = 0.0132), with lower levels in poor responders than in normal and high responders. This group effect remained after age adjustment (overall p = 0.0315), with higher concentrations in normal versus poor responders (β = 0.758, p = 0.0278) and high versus poor responders (β = 0.589, p = 0.0070). The age-adjusted AMH–melatonin association remained weakly positive (β = 0.174, 95% CI 0.022–0.327, p = 0.0250), but was no longer evident after conditioning on ovarian-response group (β = 0.011, 95% CI −0.350–0.372, p = 0.9534). In a negative-binomial model, melatonin was associated with retrieved oocyte number after age adjustment (IRR = 1.435, 95% CI 1.066–1.931, p = 0.0173), whereas the association was not retained in the exploratory group-conditioned model (IRR = 1.027, 95% CI 0.893–1.180, p = 0.7103). No consistent association was observed with downstream embryological outcomes. Conclusions: Under standardized melatonin supplementation, lower pooled follicular-fluid melatonin remained associated with the poor-response phenotype after age adjustment. However, the AMH–melatonin and melatonin–oocyte-yield associations were sensitive to the structure of the ovarian-response categories. These findings are observational and hypothesis-generating and do not establish a causal treatment effect, an independent ovarian-reserve biomarker relationship, or clinical utility.